Pharmaceuticals: Major
Argentine companies operating in the same pharmaceuticals: major industry
The table below has Argentine companies that operate under the same industry, pharmaceuticals: major. This list helps you analyze each company’s performance, income statements, and stock activity — all in one place. Sort by key metrics to find the most expensive stocks like ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25, or spot the most traded options, such as INSTITUTO ROSENBUCH SA DE BIOLOGIA. Ideal for investors and traders looking to build or refine a strategy within this growing tech segment.
Symbol | Market cap | Price | Change % | Volume | Rel Volume | P/E | EPS dil TTM | EPS dil growth TTM YoY | Div yield % TTM | Sector | Analyst Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|
 LLYDELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD)DR | 953.57 T ARS | 14.30 USD | +3.25% | 315 | 0.46 | 72.85 | 210.62 ARS | +167.86% | 0.43% | Health technology | Neutral |
| LLYCELI LILLY AND COMPANY CEDEAR EACH 4 REPR 1 ORD NPV (USD) DR | 953.57 T ARS | 14.00 USD | +0.72% | 50 | 0.00 | 71.32 | 210.62 ARS | +167.86% | 0.43% | Health technology | Neutral |
| LLYELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 DR | 953.57 T ARS | 18,050 ARS | +3.29% | 9.13 K | 1.02 | 85.70 | 210.62 ARS | +235.69% | 0.43% | Health technology | Neutral |
 JNJDJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS(USD)DR | 512.43 T ARS | 11.25 USD | 0.00% | 1.83 K | 0.87 | 20.58 | 658.51 ARS | +180.18% | 1.58% | Health technology | Neutral |
| JNJCJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS DR | 512.43 T ARS | 11.00 USD | +6.80% | 2 | 0.02 | 20.13 | 658.51 ARS | +180.18% | 1.58% | Health technology | Neutral |
| DJNJ3JOHNSON & JOHNSON CEDEAR(REPR 6.95% BDS) DR | 512.43 T ARS | 1,300 ARS | 0.00% | 27 | 2.60 | — | — | — | — | Health technology | Neutral |
| JNJJOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS DR | 512.43 T ARS | 14,275 ARS | +0.88% | 25.82 K | 1.93 | 21.68 | 658.51 ARS | +136.30% | 1.58% | Health technology | Neutral |
 ABBVDABBVIE INC CEDEAR EA 10 REP 1 COM(USD)DR | 423.91 T ARS | 19.05 USD | +1.33% | 53 | 0.68 | 9.10 | 2,245.57 ARS | +26.43% | 1.78% | Health technology | Neutral |
| ABBVABBVIE INC CEDEAR EACH 10 REPR 1 COM DR | 423.91 T ARS | 24,100 ARS | +1.80% | 361 | 0.28 | 10.73 | 2,245.57 ARS | +58.44% | 1.78% | Health technology | Neutral |
 AZNDASTRAZENECA PLC CEDEAR EA RE 0.5 ADR (USD)DR | 283.07 T ARS | 36.70 USD | +6.22% | 2 | 0.45 | 40.30 | 977.22 ARS | +96.72% | 1.51% | Health technology | Neutral |
| AZNASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25 DR | 283.07 T ARS | 46,275 ARS | +4.05% | 666 | 0.89 | 47.35 | 977.22 ARS | +146.53% | 1.51% | Health technology | Neutral |
 NVSDNOVARTIS AG CEDEAR EAC 4 REP 1(USD)DR | 281.1 T ARS | 28.55 USD | −2.23% | 2 | 0.21 | 3.81 | 9,017.02 ARS | −3.48% | 3.76% | Health technology | Neutral |
| NVSNOVARTIS AG CEDEAR EACH 4 REP 1 DR | 281.1 T ARS | 37,425 ARS | +1.15% | 123 | 0.39 | 4.15 | 9,017.02 ARS | −18.60% | 3.76% | Health technology | Neutral |
 MRKDMERCK & CO INC CEDEAR EAC 5 RE 1 (USD)DR | 265.59 T ARS | 16.80 USD | +2.44% | 272 | 0.64 | 13.53 | 1,332.07 ARS | +283.54% | 2.09% | Health technology | Neutral |
| MRKCMERCK & CO INC CEDEAR (5 REP 1 USD0.50) DR | 265.59 T ARS | 16.50 USD | −0.90% | 2 | 0.00 | 13.29 | 1,332.07 ARS | +283.54% | 2.09% | Health technology | Neutral |
| MRKMERCK & CO INC CEDEAR (5 REP 1 USD0.50) DR | 265.59 T ARS | 21,275 ARS | +2.78% | 7.24 K | 1.43 | 15.97 | 1,332.07 ARS | +380.66% | 2.09% | Health technology | Neutral |
 PFEDPFIZER INC CEDEAR 4 REP 1 ORD USD0.05(USD)DR | 181.59 T ARS | 6.36 USD | −0.16% | 4.64 K | 2.01 | 20.04 | 340.44 ARS | +582.03% | 3.65% | Health technology | Neutral |
| PFECPFIZER INC CEDEAR EACH 2 REP 1 ORD USD0.05 DR | 181.59 T ARS | 6.32 USD | +0.48% | 5 | 0.17 | 19.92 | 340.44 ARS | +582.03% | 3.65% | Health technology | Neutral |
| PFEPFIZER INC CEDEAR EACH 4 REP 1 ORD USD0.05 DR | 181.59 T ARS | 8,040 ARS | +1.13% | 29.69 K | 1.32 | 23.62 | 340.44 ARS | +754.74% | 3.65% | Health technology | Neutral |
 VRTXVERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORDDR | 154.26 T ARS | 6,000 ARS | +1.52% | 299 | 0.61 | — | −245,320.18 ARS | −133.72% | 0.00% | Health technology | Neutral |
 BMYDBRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1 USDDR | 125.54 T ARS | 16.00 USD | +0.31% | 1 | 0.01 | 19.81 | 866.77 ARS | — | 3.25% | Health technology | Neutral |
| BMYBRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1 DR | 125.54 T ARS | 20,725 ARS | +2.73% | 872 | 0.63 | 23.91 | 866.77 ARS | — | 3.25% | Health technology | Neutral |
 GSKDGSK PLC CEDEAR EACH REPR 1/4 ADR (USD)DR | 94.71 T ARS | 9.19 USD | +2.11% | 8 | 0.19 | 20.75 | 475.21 ARS | +32.57% | 3.20% | Health technology | Neutral |
| GSKGSK PLC CEDEAR EACH REPR 1/4 ADR DR | 94.71 T ARS | 12,050 ARS | +3.21% | 13.92 K | 2.56 | 25.36 | 475.21 ARS | +66.14% | 3.20% | Health technology | Neutral |
 BIIBDBIOGEN INC CEDEAR EAC 13 RE 1 COM(USD)DR | 24.17 T ARS | 10.10 USD | +2.33% | 10 | 0.07 | 14.67 | 738.48 ARS | +101.66% | 0.00% | Health technology | Neutral |
| BIIBBIOGEN INC CEDEAR EACH 13 REP 1 COM USD0.0005 DR | 24.17 T ARS | 12,725 ARS | +2.21% | 318 | 0.08 | 17.23 | 738.48 ARS | +152.73% | 0.00% | Health technology | Neutral |
 RICHLABORATORIOS RICHMOND SACIF | 109.01 B ARS | 1,350 ARS | −0.74% | 5 K | 0.48 | 5.45 | 247.77 ARS | — | 1.99% | Health technology | Neutral |
 ROSEINSTITUTO ROSENBUCH SA DE BIOLOGIA | 10.31 B ARS | 242.00 ARS | +7.68% | 305.35 K | 0.64 | — | −54.59 ARS | −355.19% | 0.00% | Health technology | Neutral |